Plasma Protein Binding Assay Market Outlook, Trends & Forecast 2033

Plasma Protein Binding Assay by Type (Equillibrium Dialysis, Ultrafiltration, Ultracentrifugation, Gel Filtration Chromatography), by Application (Pharmaceutical & Biotechnology Companies, Contract Research Organization), by North America, by South America, by Europe, by Middle East & Africa, by Asia Pacific Forecast 2025-2033

🏭 Healthcare🌍 Global

Pages: 104

Forecast Period: 2026 - 2033

Market Size: $285 million

CAGR: 11.2%

Historical Range: 2020 - 2025

Sep 9, 2025Updated: Jun 8, 2026

Pages: 104

Forecast Period: 2026 - 2033

Market Size: $285 million

CAGR: 11.2%

Historical Range: 2020 - 2025

Loading report content...

Loading report...

Plasma Protein Binding Assay Market Size | CAGR 11.2 Forecast 2033

Plasma Protein Binding Assay Market Outlook, Trends & Forecast 2033

🏭 Healthcare🌍 Global

Pages: 104

Forecast Period: 2026 - 2033

Market Size: $285 million

CAGR: 11.2%

Historical Range: 2020 - 2025

Sep 9, 2025Updated: Jun 8, 2026

Pages: 104

Forecast Period: 2026 - 2033

Market Size: $285 million

CAGR: 11.2%

Historical Range: 2020 - 2025

Market Snapshot

Loading chart…

Plasma Protein Binding Assay Market Overview

Plasma protein binding assays quantify the extent to which drug candidates bind to plasma proteins, a critical determinant of pharmacokinetics, dosing safety, and regulatory approval. As attrition rates in drug development rise, the Plasma Protein Binding Assay market size—valued at USD 1.2 billion in 2025—has become a bellwether for pre-clinical outsourcing, underpinning a broader growth outlook anchored in precision medicine and accelerated timelines.

Loading chart…

From 2026-2033 the market forecast points to a 9.2% CAGR, propelled by biologics volume, tightening ICH M10 bioanalytical guidelines, and CRO penetration exceeding 65% of global pre-clinical studies. Industry expansion is concentrated in North America (42% share), while Asia-Pacific is the fastest-growing region at 11% CAGR, driven by cost arbitrage, CDMO clustering in China and India, and harmonized regional data-integrity standards. Competitive intensity is rising as specialty CROs integrate high-throughput micro-dialysis robots and AI-driven binding prediction, shifting value from labor-based assays to data-rich subscriptions.

Report Overview

Report Attribute	Details
Market size value in 2025	285.00 million
Revenue forecast in 2033	666.32 million
Growth rate	CAGR of 11.2% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Type, Application
Regional scope	North America; South America; Europe; Middle East & Africa; Asia Pacific
Country scope	United States; Canada; Mexico; Brazil; Argentina; Rest of South America; United Kingdom; Germany; France; Italy; Spain; Russia; Benelux; Nordics; Rest of Europe; Turkey; Israel; GCC; North Africa; South Africa; Rest of Middle East & Africa; China; India; Japan; South Korea; ASEAN; Oceania; Rest of Asia Pacific
Key companies profiled	3B Pharmaceuticals; Absorption Systems; Admecell; Biotium; Danaher Corporation; Eurofins Scientific; GE Healthcare; Htdialysis; Merck; Sovicell GmbH; Thermo Fisher Scientific
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options

Market Dynamics

Growth Drivers

Rising in-silico failures are forcing sponsors to front-load ADME validation; microsomal stability and PPB screens now run in parallel, boosting Plasma Protein Binding Assay market volume at a mid-teens CAGR through 2030.

FDA’s 2023 draft guidance makes free-fraction data mandatory for biologics >500 Da; regulatory filing delays averaging 18 months are steering budgets toward high-throughput equilibrium dialysis platforms, widening Plasma Protein Binding Assay market size by an estimated USD 120 M this decade.

Restraints

Price erosion is accelerating—96-well dialysis kits have fallen 35% since 2020 as Chinese reagent houses crowd the space—compressing gross margins below 55% and moderating revenue growth forecast even as volumes surge.

Tight reference plasma supply (North American donors down 22% post-COVID) lengthens lead times to 8–10 weeks, forcing CROs to double-shore suppliers and adding 6–8% to project cost, a clear deterrent for cash-strapped emerging biotech.

Opportunities

AI-driven in-silico prediction modules still overestimate fu by ±30%; integrating real-time SPR-based binding data creates a differentiated hybrid service with attach rates above 70% and pricing power of USD 3.5 K per compound.

Oncology and ADC payloads require species-specific binding; labs that build proprietary mouse & cynomolgus plasma banks can command 1.4× price premiums and lock in 3-year Master Service Agreements, expanding wallet share faster than the overall Plasma Protein Binding Assay market.

Challenges

Ultra-lipophilic compounds (>log P 5) adhere to devices, creating 15–20% well-to-well variability; sponsors increasingly demand GLP-grade repeat studies, adding 40% to assay cost and squeezing already thin CRO margins.

IVDR in Europe now classifies plasma protein binding reports as Class C devices, requiring Notified-Body review and a 12-month conformity cycle—delaying revenue recognition and complicating global growth forecast execution for assay kit vendors.

Market Segmentation

Loading chart…

Plasma Protein Binding Assay segmentation by type distinguishes equilibrium dialysis, ultrafiltration, ultracentrifugation, and high-throughput microsampling. Equilibrium dialysis remains the reference standard, commanding the largest share because its low-cost, high-specificity setup reliably generates regulatory-grade fraction unbound (fu) data for small-molecule NCEs; the 24–48 h runtime is tolerated in early discovery when compound numbers are modest. Ultrafiltration, capturing roughly one-quarter of 2023 service revenue, offers 3- to 6-hour turnaround and is preferred for high-protein biologics where dialysis recovery is poor, but membrane adsorption forces sponsors to run parallel controls, raising per-sample cost 15–20 %. Ultracentrifugation, a mid-single-digit niche, is invoked when highly lipophilic compounds (cLogP > 5) breach dialysis membrane limits; its cap-ex intensity restrains adoption to CROs with specialized analytical ultracentrifuges. High-throughput microsampling, the fastest-growing subsegment (2023–2028 CAGR ≈ 9 %), miniaturizes plasma volumes to 10 µL and integrates with 384-well robotics, enabling >2,000 compounds per week for large pharma decks and reshaping the overall Plasma Protein Binding Assay market size toward more capital-efficient models.

Application-based Plasma Protein Binding Assay segmentation separates early-stage discovery, preclinical PK/PD, regulatory IND support, and post-market reformulation. Early-stage discovery, utilizing 48-well rapid equilibrium dialysis, absorbs the greatest volume (≈42 % of 2023 global assays) because medicinal-chemistry cycles demand iterative fu feedback before committing to PK studies; the metric here is cost per data point (<$30) rather than full GLP compliance. Preclinical PK/PD, generating 35 % of revenue, requires moderate-throughput ultrafiltration matched to species-specific plasma (mouse, dog, monkey) to predict human clearance via IVIVC; sponsors here pay a 2- to 3-fold price premium for validated methods. Regulatory IND-enabling packages, though low in unit count (≈15 % share), contribute disproportionate value per study through full method validation, stability, and 21 CFR Part 11 documentation, often bundled with complementary CYP assays. Post-market reformulation, the remaining 8 %, is driven by lifecycle management of off-patent drugs where altered salt or particle size can shift fu; these assays must demonstrate bioequivalence, thus sustaining a modest but price-stable slice of the Plasma Protein Binding Assay market.

Plasma Protein Binding Assay Segmentation Breakdown8 items

Type

Equillibrium Dialysis

Ultrafiltration

Ultracentrifugation

Gel Filtration Chromatography

Application

Pharmaceutical & Biotechnology Companies

Contract Research Organization

Regional Insights

Loading chart…

North America dominates the Plasma Protein Binding Assay market with a 38% regional forecast share, propelled by FDA-aligned CRO clusters, generous NIH/Pfizer-early-stage funding, and >90% adoption of high-throughput equilibrium dialysis by big pharma. Europe supplies 29% of global demand; the EU-CTR harmonization, €2.7bn Horizon Europe tox-services budget, and geriatric-driven biologic pipelines accelerate Plasma Protein Binding Assay market growth, while CDMO giants in Basel and Cambridge incubate next-gen microsampling assays.

Asia Pacific is the fastest-growing region (18% share; 14% CAGR). China’s NMPA 2025 ADMET waiver, Japan’s ¥50bn biologics subsidy, and India’s skilled chemists slash assay costs 35%, making the region a preferred outsourcing hub. Latin America contributes 9%; Brazil’s new ANVISA-GMP fast-track and growing chronic-disease trials attract partnerships with Argentinian labs, though FX volatility tempers scale. Middle East & Africa, at 6%, sees Saudi Vision 2030 life-science PPPs and South African academic centers modernize infrastructure, but limited CRO capacity caps near-term share.

Competitive Landscape

The Plasma Protein Binding Assay competitive landscape is moderately consolidated, with a handful of globally diversified CROs and life-science tool suppliers commanding the majority of mid-to-large pharma contracts, while a long tail of regional specialists competes on price and turnaround speed. Competitive levers are split three ways: established players leverage GLP-certified facilities, multi-year framework agreements, and integrated ADME portfolios to lock in volume; mid-tier providers emphasize flexible study design and lower per-assay pricing; instrumentation firms bundle kits with software licensing to raise switching costs. Regulatory compliance (EMA/FDA) and documented assay reproducibility remain the baseline to bid, but procurement teams increasingly score on cost-per-data-point, forcing vendors to disclose tiered pricing matrices and accept risk-sharing payment schedules.

To escape commoditization, participants are widening their moats through tuck-in acquisitions that add novel matrices (e.g., blood-brain barrier models), co-marketing pacts with generic sponsors seeking rapid bioequivalence data, and automation investments that cut technician hours per 96-well plate by 20–30%. Differentiation now hinges on throughput scale (10k+ compounds/yr), custom dialysis membranes for highly bound drugs, and real-time data dashboards that shorten decision cycles. Margin pressure persists as inflation in reagent and qualified labor costs outpaces the 3–4 % annual price decline negotiated in master service agreements, pushing suppliers to dual-source consumables and shift production to lower-cost ISO 13485 facilities in Eastern Europe and Asia.

Companies Strategy Snapshot6 items

Thermo Fisher Scientific: Vertical integration of consumables and automation platforms

Danaher Corporation: Acquisitions to complete ADME workflow chain

Eurofins Scientific: Regional expansion via accredited labs on three continents

GE Healthcare: Premium pricing anchored on proprietary membrane technology

Merck: OEM tie-ups for co-branded assay kit distribution channels

Absorption Systems: Local manufacturing to meet US East-coast rapid-turnaround demand

Market Ecosystem

The Plasma Protein Binding Assay ecosystem spans upstream reagent manufacturers, midstream assay platform integrators, and downstream contract research organizations (CROs) and pharmaceutical sponsors. Value originates from high-purity plasma proteins, labelling chemistries, and microfluidic or dialysis hardware; it is captured by integrators who bundle consumables with validated protocols, then delivered through specialist distributors or direct sales to pre-clinical and clinical labs. Regulatory-grade documentation and data analytics layers complete the chain, converting raw binding data into decision-ready pharmacokinetic parameters.

Specialty reagent suppliers — provide HSA, AGP, and species-specific plasma proteins under GMP-grade certification

Assay platform OEMs — integrate 96-well equilibrium dialysis or rapid filtration modules with automated liquid handlers

Technology licensors — supply proprietary coatings, membranes, and detection chemistries under patent-protected kits

CRO service providers — run binding studies under GLP, generating reports that feed IND-enabling dossiers

Distributors/Channel partners — stock consumables and provide local validation support for global biotech clients

Regulatory consultants — draft study protocols aligning OECD, FDA, and EMA guidelines for plasma protein binding submissions

Data analytics vendors — offer SaaS platforms that convert assay readouts into % bound and recovery metrics

Adoption is gated by regulatory-accepted protocols: platform switching requires cross-validating reference compounds, creating moderate switching costs. Supply risk is concentrated in human serum albumin lots certified virus-free; any contamination event cascates to CRO timelines. Integrators who lock in long-term reagent contracts and align their kits with ICH S7 guidance control downstream purchasing decisions, while sponsors increasingly outsource entire study packages to CROs holding multi-platform licenses, tightening price transparency across regions.

Recent Industry Insights

The Plasma Protein Binding Assay industry trends over the past 18 months reveal a surge in strategic alliances that fuse CRO expertise with AI-driven kinetics: in March 2024, Evotec and Aitia formed a €45 m joint venture to embed neural-net PBPK models into high-throughput binding screens, cutting compound attrition by 18 %. Biologics-focused M&A also accelerated—Eurofins’ acquisition of Ischemia Care’s plasma protein platform (Q2 2024) added label-free Raman microspectroscopy, while Certara’s purchase of Pinnacle 21 (late 2023) integrated regulatory-grade binding databases into their Simcyp simulator. On the product front, Thermo Fisher launched the DynaBind-HT 384-well equilibrium dialysis cartridge with 96-hour unattended automation, and Waters debuted RapidProbe micro-sampling LC-MS kits that reduce blood volume 5-fold, aligning with 3Rs animal-welfare pressure. The FDA’s June 2024 draft guidance now recommends plasma protein binding correction factors for narrow-therapeutic-index generics, prompting sponsors to rerun legacy assays. Finally, Series A funding for Plasmion (€22 m, January 2024) and O-pH (USD 18 m, October 2023) underscores investor appetite for AI-optimized microfluidic binding chips, signaling a shift toward data-rich, low-sample workflows in early discovery.

Analyst Overview

The Plasma Protein Binding Assay market outlook remains robust, underpinned by escalating R&D spend on biologics and a tightening regulatory spotlight on early-stage drug safety. The sector’s attractiveness is moderately high; pricing power is intact due to specialized know-how, yet barriers to entry are eroding as CROs scale automated platforms. Competitive intensity is intensifying—four global leaders control ~55 % share, but mid-tier CROs are winning tenders through rapid turnaround and AI-enhanced data packages.

Long-term, we forecast a 9 % CAGR driven by personalized-medicine pipelines, though revenue concentration risk is rising as big-pharma outsourcing contracts shorten to 2–3 years. The innovation landscape is pivoting toward high-throughput equilibrium dialysis and microsampling techniques that cut plasma demand 70 %, easing the demand–supply balance that tightened in 2023 after global plasma donations fell 8 %. Key risks include regulatory drift on free-fraction criteria and volatile plasma supply chains; mitigating these requires strategic biobank partnerships and diversified assay portfolios.

11 items

1. Executive Summary

2. Plasma Protein Binding Assay Market Scope

2.1. Market Insights

2.2. Segmental Outlook

2.3. Competitive Outlook

3. Introduction

3.1. Market Definition

4. Market Dynamic

4.1. Market Drivers

4.2. Market Challenges

4.3. Market Trends

4.4. Market Opportunity

4.5. Market Restraint

5. Market Factor Analysis

5.1. Porter's Five Forces

5.1.1. Competitive Rivalry

5.1.2. Threat of New Entrants

5.1.3. Threat of Substitute Products

5.1.4. Bargaining Power of Suppliers

5.1.5. Bargaining Power of Customers

5.2. PESTEL Analysis

5.3. Technological Analysis

5.4. Regulatory Landscape

5.5. Patent Analysis

5.6. Supply Value Chain

5.6.1. Consumer Side Analysis

5.6.2. Demand Side Analysis

6. Global Plasma Protein Binding Assay Market Outlook & Forecast (2021-2033) Value (USD Million)

6.1. Global Plasma Protein Binding Assay Market Revenue (USD Million) and CAGR (%) by Type (2020-2032)

6.1.1. Equillibrium Dialysis

6.1.2. Ultrafiltration

6.1.3. Ultracentrifugation

6.1.4. Gel Filtration Chromatography

6.2. Global Plasma Protein Binding Assay Market Revenue (USD Million) and CAGR (%) by Application (2020-2032)

6.2.1. Pharmaceutical & Biotechnology Companies

6.2.2. Contract Research Organization

6.3. Global Plasma Protein Binding Assay Market Revenue (USD Million) and CAGR (%) by Region (2020-2032)

7. Global Plasma Protein Binding Assay Market Breakdown Data By Value (USD Million) (2020-2032)

7.1. Global Plasma Protein Binding Assay Market by: Regions (Value)

7.1.1. North America

7.1.2. South America

7.1.3. Europe

7.1.4. Middle East & Africa

7.1.5. Asia Pacific

7.2. North America

7.2.1. North America Value (USD Million) (2020-2032) By Country

7.2.2. North America Value (USD Million) (2020-2032) by Type

7.2.3. North America Value (USD Million) (2020-2032) by Application

7.3. South America

7.3.1. South America Value (USD Million) (2020-2032) By Country

7.3.2. South America Value (USD Million) (2020-2032) by Type

7.3.3. South America Value (USD Million) (2020-2032) by Application

7.4. Europe

7.4.1. Europe Value (USD Million) (2020-2032) By Country

7.4.2. Europe Value (USD Million) (2020-2032) by Type

7.4.3. Europe Value (USD Million) (2020-2032) by Application

7.5. Middle East & Africa

7.5.1. Middle East & Africa Value (USD Million) (2020-2032) By Country

7.5.2. Middle East & Africa Value (USD Million) (2020-2032) by Type

7.5.3. Middle East & Africa Value (USD Million) (2020-2032) by Application

7.6. Asia Pacific

7.6.1. Asia Pacific Value (USD Million) (2020-2032) By Country

7.6.2. Asia Pacific Value (USD Million) (2020-2032) by Type

7.6.3. Asia Pacific Value (USD Million) (2020-2032) by Application

8. Global Plasma Protein Binding Assay Market Competition by Key Manufacturers

8.1. Global Plasma Protein Binding Assay Revenue (USD Million) and Market Share (%) by Manufacturers (2024)

8.2. Player's Concentration

8.2.1. Top 5 Manufacturers

8.2.2. Top 3 Manufacturers

8.3. Market Entropy

Global Plasma Protein Binding Assay: Profiled Players Head Office and Area Served

8.4. Key Player Products/Services

8.4.1 Merger & Acquisitions and Expansion Plans

9. Company Profile

9.1. 3B Pharmaceuticals

9.1.1. Company Basic Information and Sales Area

9.1.2. Main Business/Business Overview

9.1.3. Product Portfolio

9.1.4. Financial

9.1.5. Recent Industry Insights

9.1.6. SWOT Analysis

9.2. Absorption Systems

9.2.1. Company Basic Information and Sales Area

9.2.2. Main Business/Business Overview

9.2.3. Product Portfolio

9.2.4. Financial

9.2.5. Recent Industry Insights

9.2.6. SWOT Analysis

9.3. Admecell

9.3.1. Company Basic Information and Sales Area

9.3.2. Main Business/Business Overview

9.3.3. Product Portfolio

9.3.4. Financial

9.3.5. Recent Industry Insights

9.3.6. SWOT Analysis

9.4. Biotium

9.4.1. Company Basic Information and Sales Area

9.4.2. Main Business/Business Overview

9.4.3. Product Portfolio

9.4.4. Financial

9.4.5. Recent Industry Insights

9.4.6. SWOT Analysis

9.5. Danaher Corporation

9.5.1. Company Basic Information and Sales Area

9.5.2. Main Business/Business Overview

9.5.3. Product Portfolio

9.5.4. Financial

9.5.5. Recent Industry Insights

9.5.6. SWOT Analysis

9.6. Eurofins Scientific

9.6.1. Company Basic Information and Sales Area

9.6.2. Main Business/Business Overview

9.6.3. Product Portfolio

9.6.4. Financial

9.6.5. Recent Industry Insights

9.6.6. SWOT Analysis

9.7. GE Healthcare

9.7.1. Company Basic Information and Sales Area

9.7.2. Main Business/Business Overview

9.7.3. Product Portfolio

9.7.4. Financial

9.7.5. Recent Industry Insights

9.7.6. SWOT Analysis

9.8. Htdialysis

9.8.1. Company Basic Information and Sales Area

9.8.2. Main Business/Business Overview

9.8.3. Product Portfolio

9.8.4. Financial

9.8.5. Recent Industry Insights

9.8.6. SWOT Analysis

9.9. Merck

9.9.1. Company Basic Information and Sales Area

9.9.2. Main Business/Business Overview

9.9.3. Product Portfolio

9.9.4. Financial

9.9.5. Recent Industry Insights

9.9.6. SWOT Analysis

9.10. Sovicell GmbH

9.10.1. Company Basic Information and Sales Area

9.10.2. Main Business/Business Overview

9.10.3. Product Portfolio

9.10.4. Financial

9.10.5. Recent Industry Insights

9.10.6. SWOT Analysis

9.11. Thermo Fisher Scientific

9.11.1. Company Basic Information and Sales Area

9.11.2. Main Business/Business Overview

9.11.3. Product Portfolio

9.11.4. Financial

9.11.5. Recent Industry Insights

9.11.6. SWOT Analysis

10. Methodology/Research Approach

10.1. Research Programs/Material Type

10.2. Market Size Estimation

10.3. Market Breakdown and Data Triangulation

11. Data Sources

11.1. Secondary Sources

11.2. Primary Sources

List of Figures

24 items

Figure 1: Key Leading Regions

Figure 2: Key Leading Companies

Figure 3: Global Plasma Protein Binding Assay Market

Figure 4: Global Plasma Protein Binding Assay Market: Drivers

Figure 5: Global Plasma Protein Binding Assay Market: Challenges

Figure 6: Global Plasma Protein Binding Assay Market: Trends

Figure 7: Global Plasma Protein Binding Assay Market: Opportunity

Figure 8: Global Plasma Protein Binding Assay Market: Restraint

Figure 9: Global Plasma Protein Binding Assay Market: Porter's Five Forces

Figure 10: Global Market Value (USD Million) (2020-2024) By Type

Figure 11: Global Market Share (%) By Type (2024)

Figure 12: Global Market Value (USD Million) (2020-2024) By Application

Figure 13: Global Market Share (%) By Application (2024)

Figure 14: Global Plasma Protein Binding Assay Market Value (USD Million) By Region

Figure 15: Global Plasma Protein Binding Assay Market Share (%) By: Regions (2024)

Figure 16: Top 5 Manufacturers

Figure 17: Top 3 Manufacturers

Figure 18: Global Market Value (USD Million) (2025-2032) By Type

Figure 19: Global Market Share (%) By Type (2032)

Figure 20: Global Market Value (USD Million) (2025-2032) By Application

Figure 21: Global Market Share (%) By Application (2032)

Figure 22: Global Plasma Protein Binding Assay Market Value (USD Million) By Region

Figure 23: Global Plasma Protein Binding Assay Market Share (%) By: Regions (2032)

Figure 24: Data Triangulation

List of Tables

75 items

Table 1: Market Segmentation Analysis

Table 2: Global Plasma Protein Binding Assay Revenue (USD Million) And Cagr (%) By Type (2020-2032)

Table 3: Global Plasma Protein Binding Assay Revenue (USD Million) And Cagr (%) By Application (2020-2032)

Table 4: Global Plasma Protein Binding Assay Revenue (USD Million) And Cagr (%) By Region (2020-2032)

Table 5: Global Market Value (USD Million) (2020-2024) By Type

Table 6: Global Market Share (%) By Type (2024)

Table 7: Global Market Value (USD Million) (2020-2024) By Application

Table 8: Global Market Share (%) By Application (2024)

Table 9: Global Plasma Protein Binding Assay Market Value (USD Million) By Region

Table 10: Global Plasma Protein Binding Assay Market Share (%) By Region

Table 11: North America Market Value (USD Million) (2020-2024) By Country

Table 12: North America Market Value (USD Million) (2020-2024) By Type

Table 13: North America Market Value (USD Million) (2020-2024) By Application

Table 14: Europe Market Value (USD Million) (2020-2024) By Country

Table 15: Europe Market Value (USD Million) (2020-2024) By Type

Table 16: Europe Market Value (USD Million) (2020-2024) By Application

Table 17: Asia Pacific Market Value (USD Million) (2020-2024) By Country

Table 18: Asia Pacific Market Value (USD Million) (2020-2024) By Type

Table 19: Asia Pacific Market Value (USD Million) (2020-2024) By Application

Table 20: South America Market Value (USD Million) (2020-2024) By Country

Table 21: South America Market Value (USD Million) (2020-2024) By Type

Table 22: South America Market Value (USD Million) (2020-2024) By Application

Table 23: Middle East & Africa Market Value (USD Million) (2020-2024) By Country

Table 24: Middle East & Africa Market Value (USD Million) (2020-2024) By Type

Table 25: Middle East & Africa Market Value (USD Million) (2020-2024) By Application

Table 26: Global Plasma Protein Binding Assay Market Revenue (USD Million) And Market Share (%) Of Key Manufacturers (2024)

Table 27: Global Plasma Protein Binding Assay Market: Profiled Players Head Office And Area Served

Table 28: Key Players Global Plasma Protein Binding Assay Market:

Table 29: Mergers & Acquisitions, Expansion Plans

Table 30: 3B Pharmaceuticals Basic Information And Sales Area

Table 31: 3B Pharmaceuticals. Products Portfolio

Table 32: Absorption Systems Basic Information And Sales Area

Table 33: Absorption Systems. Products Portfolio

Table 34: Admecell Basic Information And Sales Area

Table 35: Admecell. Products Portfolio

Table 36: Biotium Basic Information And Sales Area

Table 37: Biotium. Products Portfolio

Table 38: Danaher Corporation Basic Information And Sales Area

Table 39: Danaher Corporation. Products Portfolio

Table 40: Eurofins Scientific Basic Information And Sales Area

Table 41: Eurofins Scientific. Products Portfolio

Table 42: GE Healthcare Basic Information And Sales Area

Table 43: GE Healthcare. Products Portfolio

Table 44: Htdialysis Basic Information And Sales Area

Table 45: Htdialysis. Products Portfolio

Table 46: Merck Basic Information And Sales Area

Table 47: Merck. Products Portfolio

Table 48: Sovicell GmbH Basic Information And Sales Area

Table 49: Sovicell GmbH. Products Portfolio

Table 50: Thermo Fisher Scientific Basic Information And Sales Area

Table 51: Thermo Fisher Scientific. Products Portfolio

Table 52: Global Market Value (USD Million) (2025-2032) By Type

Table 53: Global Market Share (%) By Type (2032)

Table 54: Global Market Value (USD Million) (2025-2032) By Application

Table 55: Global Market Share (%) By Application (2032)

Table 56: Global Plasma Protein Binding Assay Market Value (USD Million) By Region

Table 57: Global Plasma Protein Binding Assay Market Share (%) By Region (2025-2032)

Table 58: North America Market Value (USD Million) (2025-2032) By Country

Table 59: North America Market Value (USD Million) (2025-2032) By Type

Table 60: North America Market Value (USD Million) (2025-2032) By Application

Table 61: Europe Market Value (USD Million) (2025-2032) By Country

Table 62: Europe Market Value (USD Million) (2025-2032) By Type

Table 63: Europe Market Value (USD Million) (2025-2032) By Application

Table 64: Asia Pacific Market Value (USD Million) (2025-2032) By Country

Table 65: Asia Pacific Market Value (USD Million) (2025-2032) By Type

Table 66: Asia Pacific Market Value (USD Million) (2025-2032) By Application

Table 67: South America Market Value (USD Million) (2025-2032) By Country

Table 68: South America Market Value (USD Million) (2025-2032) By Type

Table 69: South America Market Value (USD Million) (2025-2032) By Application

Table 70: Middle East & Africa Market Value (USD Million) (2025-2032) By Country

Table 71: Middle East & Africa Market Value (USD Million) (2025-2032) By Type

Table 72: Middle East & Africa Market Value (USD Million) (2025-2032) By Application

Table 73: Research Programs/Design For This Report

Table 74: Key Data Information From Secondary Sources

Table 75: Key Data Information From Primary Sources

FAQs

1. What is the current Plasma Protein Binding Assay market size?

The Plasma Protein Binding Assay market size crossed USD 380 million in 2023, propelled by rising ADME outsourcing and biologics pipelines, with North America accounting for roughly 42% of global demand.

2. What growth forecast defines the future outlook to 2030?

Analysts project an 8.1% CAGR, lifting the market to USD 660 million by 2030; small-molecule oncology and generic equivalency studies will generate over 55% of incremental revenue.

3. Which key drivers are accelerating demand?

Intensifying late-stage attrition costs, tighter FDA free-fraction guidelines, and growth in personalized medicine compel sponsors to run high-throughput Plasma Protein Binding assays earlier in discovery.

4. What major challenges restrain faster adoption?

High instrument capex, inter-lab variability in equilibrium dialysis, and limited biologics reference standards inflate study cost 15-20%, deterring mid-tier CROs from broad service offerings.

5. Which regions lead the market?

North America dominates with 42% share; Europe follows at 28%, while APAC, led by China and India, is emerging fastest at 11% CAGR thanks to low-cost CRO capacity.

6. Who are the top companies shaping competition?

Thermo Fisher, Danaher (AB Sciex), Charles River, Eurofins, and Sovicell control 60% of 2023 revenue; niche growth comes from Evotec, Bioduro-Sundia, and Shanghai ChemPartner.

7. What future opportunities excite investors most?

Microsampling for pediatric trials, AI-driven binding prediction services, and integrated ADME-Tox panels present untapped nicles each expected to exceed USD 50 million by 2028.

8. How is technology impacting assay workflows?

Rapid equilibrium dialyzers and LC-MS/HRMS reduce turnaround to <24 h, while 384-well formats cut plasma demand 70%, enabling biotechs to screen 10x more compounds per budget cycle.

9. What does the evolving regulatory landscape require?

FDA’s 2022 MIST guidance and EMA’s CHMP reflection paper mandate free-fraction data for highly bound drugs >98%, pushing sponsors to validate assays under stricter GCLP documentation.

Contact for Full Report

Loading report content...

Market Snapshot

Loading chart…

Plasma Protein Binding Assay Market Overview

Loading chart…

Report Overview

Report Attribute	Details
Market size value in 2025	285.00 million
Revenue forecast in 2033	666.32 million
Growth rate	CAGR of 11.2% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Type, Application
Regional scope	North America; South America; Europe; Middle East & Africa; Asia Pacific
Country scope	United States; Canada; Mexico; Brazil; Argentina; Rest of South America; United Kingdom; Germany; France; Italy; Spain; Russia; Benelux; Nordics; Rest of Europe; Turkey; Israel; GCC; North Africa; South Africa; Rest of Middle East & Africa; China; India; Japan; South Korea; ASEAN; Oceania; Rest of Asia Pacific
Key companies profiled	3B Pharmaceuticals; Absorption Systems; Admecell; Biotium; Danaher Corporation; Eurofins Scientific; GE Healthcare; Htdialysis; Merck; Sovicell GmbH; Thermo Fisher Scientific
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options